Immunoact Announces Partnership with Mango Sciences to Bring the World’s First Bridge Financing Plan and Value-Based Offering For CAR-T Therapy for Cancer Patients in India
New Delhi [India], December 2: Partnership enables ImmunoACT to offer eligible patients a bridge financing plan and value-based offering to access its NexCAR19TM CAR-T therapy for leukaemia and lymphoma. Mumbai, India, December 2: ImmunoAdoptive Cell Therapy (ImmunoACT), the Mumbai, India-based pioneering research and cell and gene therapy development company, announced a strategic partnership with Mango Sciences, [...]
New Delhi [India], December 2: Partnership enables ImmunoACT to offer eligible patients a bridge financing plan and value-based offering to access its NexCAR19TM CAR-T therapy for leukaemia and lymphoma.
Mumbai, India, December 2: ImmunoAdoptive Cell Therapy (ImmunoACT), the Mumbai, India-based pioneering research and cell and gene therapy development company, announced a strategic partnership with Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, to expand access and affordability of ImmunoACT’s NexCAR19TM chimeric antigen receptor T-cell (CAR-T) for leukaemia and lymphoma. The partnership will enable patients to avail easy 0% interest EMI plans of up to 10 lakhs to cover the cost of CAR-T. Additionally, a value-based offering of up to ₹10 lakhs can also be availed by clinically eligible patients.
NexCAR19TM is a first-of-its-kind product that has given patients in India access to this lifesaving, leading-edge therapy at an affordable price, and this partnership is aimed at making this treatment accessible for more patients in India. The Mango Sciences plan benefit will be available initially at select health care facilities to patients who take NexCAR19TM.
